Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Ann Surg. 2021 Dec 1;274(6):1058–1066. doi: 10.1097/SLA.0000000000003770

TABLE 5.

Clinicopathologic Features of Patients Who Received Adjuvant Chemotherapy or Chemotherapy Followed by Radiation After Resection of Pancreatic Cancer

Categorical Variable Chemo Chemo-RT P Value
Median survival (mo) 21.0 24.8 <0.0001
Grade
  1 266 (8.3%) 288 (8.9%) 0.622
  2 1692 (52.5%) 1668 (51.8%)
  3 1227 (38.1%) 1235 (38.3%)
  4 38 (1.2%) 31 (1.0%)
Stage
  1 79 (2.3%) 84 (2.5%) 0.897
  2 3224 (94.3%) 3223 (94.3%)
  3 115 (3.4%) 111 (3.2%)
T
  1 79 (2.3%) 79 (2.3%) 0.999
  2 296 (8.8%) 297 (8.8%)
  3 2912 (86.4%) 2910 (86.4%)
  4 83 (2.5%) 84 (2.5%)
Comorbidities
  No 2294 (67.1%) 2328 (68.1%) 0.394
  Yes 1124 (32.7%) 1090 (31.9%)
Tumor size (mm) 35.8±25.9 36.0±35.0 0.814
# of examined nodes 18.0±9.6 18.0±9.6 0.847
# of positive nodes 3.50±3.42 3.41±3.40 0.288
LNR 0.22±0.21 0.21±0.20 0.366

The cohort of propensity score matching of patients with at least 1 high-risk pathologic feature (margin involvement and/or nodal involvement and/or lymphovascular invasion).

All the treatments are in the adjuvant setting. Categorical variables presented in number (%) and continuous variables presented as mean standard deviation.

Chemo indicates chemotherapy; Chemo-RT, chemotherapy followed by radiation; LNR, Lymph node ratio.